Paola Dongiovanni

List of Publications by Year
in descending order

177	11,226	23500	32761
papers	citations	58 h-index	100 g-index

183	183	183	10292
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology, 2010, 51, 1209-1217.	3.6	563
2	The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. Gastroenterology, 2016, 150, 1219-1230.e6.	0.6	506
3	Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology, 2015, 61, 506-514.	3.6	424
4	Statin use and non-alcoholic steatohepatitis in at risk individuals. Journal of Hepatology, 2015, 63, 705-712.	1.8	309
5	PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Human Molecular Genetics, 2014, 23, 4077-4085.	1.4	293
6	Tumor necrosis factor Î± promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology, 2002, 122, 274-280.	0.6	285
7	Iron in fatty liver and in the metabolic syndrome: A promising therapeutic target. Journal of Hepatology, 2011, 55, 920-932.	1.8	279
8	Iron Depletion by Phlebotomy Improves Insulin Resistance in Patients With Nonalcoholic Fatty Liver Disease and Hyperferritinemia: Evidence from a Case-Control Study. American Journal of Gastroenterology, 2007, 102, 1251-1258.	0.2	274
9	Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. Journal of Internal Medicine, 2018, 283, 356-370.	2.7	256
10	I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology, 2010, 52, 1274-1280.	3.6	252
11	HFE Genotype, Parenchymal Iron Accumulation, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2010, 138, 905-912.	0.6	246
12	Patatin-Like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology, 2011, 53, 791-799.	3.6	227
13	PNPLA3 I148M polymorphism and progressive liver disease. World Journal of Gastroenterology, 2013, 19, 6969.	1.4	207
14	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. Scientific Reports, 2017, 7, 4492.	1.6	193
15	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. Journal of Hepatology, 2021, 74, 775-782.	1.8	193
16	Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment. Current Pharmaceutical Design, 2013, 19, 5219-5238.	0.9	184
17	Increased Expression and Activity of the Transcription Factor FOXO1 in Nonalcoholic Steatohepatitis. Diabetes, 2008, 57, 1355-1362.	0.3	163
18	The SOD2 C47T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies. Journal of Hepatology, 2012, 56, 448-454.	1.8	156

#	Article	IF	Citations
19	Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis. Science Translational Medicine, 2018, 10, .	5.8	151
20	Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut, 2010, 59, 267-273.	6.1	148
21	Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. Clinical Gastroenterology and Hepatology, 2017, 15, 1604-1611.e1.	2.4	146
22	Iron Depletion by Deferoxamine Up-Regulates Glucose Uptake and Insulin Signaling in Hepatoma Cells and in Rat Liver. American Journal of Pathology, 2008, 172, 738-747.	1.9	144
23	Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis. Cell Metabolism, 2020, 31, 406-421.e7.	7.2	141
24	Dietary Iron Overload Induces Visceral Adipose Tissue Insulin Resistance. American Journal of Pathology, 2013, 182, 2254-2263.	1.9	128
25	Liver fat accumulation is associated with circulating PCSK9. Annals of Medicine, 2016, 48, 384-391.	1.5	119
26	Hepatocellular carcinoma in nonalcoholic fatty liver: Role of environmental and genetic factors. World Journal of Gastroenterology, 2014, 20, 12945.	1.4	117
27	Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis. BioMed Research International, 2015, 2015, 1-10.	0.9	116
28	MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. Journal of Hepatology, 2016, 64, 682-690.	1.8	106
29	Alcohol or Gut Microbiota: Who Is the Guilty?. International Journal of Molecular Sciences, 2019, 20, 4568.	1.8	106
30	Nutritional therapy for nonalcoholic fatty liver disease. Journal of Nutritional Biochemistry, 2016, 29, 1-11.	1.9	100
31	miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis. International Journal of Molecular Sciences, 2018, 19, 3966.	1.8	98
32	The rs2294918 E434K variant modulates patatinâ€like phospholipase domainâ€containing 3 expression and liver damage. Hepatology, 2016, 63, 787-798.	3.6	93
33	Tumor necrosis factor Î± promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis. Blood, 2001, 97, 3707-3712.	0.6	88
34	Î±1-Antitrypsin mutations in NAFLD: High prevalence and association with altered iron metabolism but not with liver damage. Hepatology, 2006, 44, 857-864.	3.6	88
35	PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis. Human Molecular Genetics, 2016, 25, ddw341.	1.4	86
36	Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Scientific Reports, 2019, 9, 3682.	1.6	85

#	Article	IF	Citations
37	A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. World Journal of Gastroenterology, 2014, 20, 3002.	1.4	85
38	Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. Digestive and Liver Disease, 2003, 35, 172-178.	0.4	84
39	Genetics of nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2016, 65, 1026-1037.	1.5	84
40	The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids. Scientific Reports, 2019, 9, 11585.	1.6	82
41	The mitochondrial superoxide dismutase A16V polymorphism in the cardiomyopathy associated with hereditary haemochromatosis. Journal of Medical Genetics, 2004, 41, 946-950.	1.5	81
42	The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies. Nutrients, 2019, 11, 2642.	1.7	81
43	Iron and insulin resistance. Alimentary Pharmacology and Therapeutics, 2005, 22, 61-63.	1.9	80
44	Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 568-575.	1.1	78
45	Serum Hepcidin and Macrophage Iron Correlate With MCP-1 Release and Vascular Damage in Patients With Metabolic Syndrome Alterations. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 683-690.	1.1	78
46	PNPLA3 I148M Variant Influences Circulating Retinol in Adults with Nonalcoholic Fatty Liver Disease or Obesity ,. Journal of Nutrition, 2015, 145, 1687-1691.	1.3	78
47	Interferon lambda 4 rs368234815 TT>ÎŤG variant is associated with liver damage in patients with nonalcoholic fatty liver disease. Hepatology, 2017, 66, 1885-1893.	3.6	75
48	Genetic and Epigenetic Modifiers of Alcoholic Liver Disease. International Journal of Molecular Sciences, 2018, 19, 3857.	1.8	75
49	Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker. Gut, 2020, 69, 1855-1866.	6.1	75
50	The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. Journal of Hepatology, 2011, 55, 1409-1414.	1.8	74
51	Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes. EBioMedicine, 2020, 52, 102658.	2.7	71
52	Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B. Hepatology, 2013, 58, 1245-1252.	3.6	69
53	Iron-Dependent Regulation of MDM2 Influences p53 Activity and Hepatic Carcinogenesis. American Journal of Pathology, 2010, 176, 1006-1017.	1.9	68
54	Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis. Haematologica, 2007, 92, 1037-1042.	1.7	66

#	Article	IF	Citations
55	Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2310-2319.e6.	2.4	66
56	Hepatic iron is the major determinant of serum ferritin in <scp>NAFLD</scp> patients. Liver International, 2018, 38, 164-173.	1.9	65
57	Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease. Clinical Science, 2017, 131, 1301-1315.	1.8	64
58	Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease. PLoS ONE, 2016, 11, e0163069.	1.1	63
59	The i148m Pnpla3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls. BMC Gastroenterology, 2012, 12, 111.	0.8	62
60	Beta-globin mutations are associated with parenchymal siderosis and fibrosis in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2010, 53, 927-933.	1.8	60
61	Nutrition and Genetics in NAFLD: The Perfect Binomium. International Journal of Molecular Sciences, 2020, 21, 2986.	1.8	60
62	LPIN1 rs13412852 Polymorphism in Pediatric Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2012, 54, 588-593.	0.9	59
63	Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending?. Metabolism: Clinical and Experimental, 2021, 117, 154708.	1.5	59
64	TNF alpha polymorphisms, HFE gene mutations and acquired factors in Italian patients with porphyria cutanea tarda. Journal of Hepatology, 2002, 36, 157-158.	1.8	58
65	PNPLA3 I148M variant and hepatocellular carcinoma: A common genetic variant for a rare disease. Digestive and Liver Disease, 2013, 45, 619-624.	0.4	55
66	A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2017, 18, 1534.	1.8	54
67	Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study. BMC Gastroenterology, 2010, 10, 102.	0.8	53
68	Relationship between TNF-Î± and iron metabolism in differentiating human monocytic THP-1 cells. British Journal of Haematology, 2000, 110, 978-984.	1.2	52
69	Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. Hepatology, 2015, 62, 111-117.	3.6	52
70	Serum coding and nonâ€coding RNAs as biomarkers of NAFLD and fibrosis severity. Liver International, 2019, 39, 1742-1754.	1.9	51
71	Patatin-like phospholipase domain containing-3gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis. World Journal of Gastroenterology, 2012, 18, 2813.	1.4	50
72	Hepatocyte TLR4 triggers inter-hepatocyte Jagged1/Notch signaling to determine NASH-induced fibrosis. Science Translational Medicine, 2021, 13, .	5.8	49

#	Article	IF	Citations
73	Î²-Klotho gene variation is associated with liver damage in children with NAFLD. Journal of Hepatology, 2020, 72, 411-419.	1.8	48
74	High Fat Diet Subverts Hepatocellular Iron Uptake Determining Dysmetabolic Iron Overload. PLoS ONE, 2015, 10, e0116855.	1.1	47
75	The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development â€“ a potential therapeutic target?. Expert Review of Gastroenterology and Hepatology, 2016, 10, 229-242.	1.4	44
76	TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in InÂVitro Models. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 759-788.	2.3	44
77	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. Cancer Medicine, 2017, 6, 1930-1940.	1.3	43
78	Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2012, 18, 3782.	1.4	43
79	The A736V TMPRSS6 Polymorphism Influences Hepatic Iron Overload in Nonalcoholic Fatty Liver Disease. PLoS ONE, 2012, 7, e48804.	1.1	42
80	Fibronectin Type III Domainâ€“Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2660-2669.	1.8	42
81	PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. Journal of Lipid Research, 2019, 60, 1144-1153.	2.0	42
82	PNPLA3 I148M Polymorphism, Clinical Presentation, and Survival in Patients with Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e75982.	1.1	42
83	The <scp>UCP</scp>2 â€866ÂG>A promoter region polymorphism is associated with nonalcoholic steatohepatitis.. Liver International, 2015, 35, 1574-1580.	1.9	41
84	Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease. PLoS ONE, 2016, 11, e0162473.	1.1	41
85	Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD. Journal of Hepatology, 2021, 75, 506-513.	1.8	40
86	A Promoter Polymorphism in the Liver-specific Fatty Acid Transport Protein 5 is Associated with Features of the Metabolic Syndrome and Steatosis. Hormone and Metabolic Research, 2010, 42, 854-859.	0.7	38
87	Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease. Hepatology Communications, 2018, 2, 666-675.	2.0	38
88	MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD. EBioMedicine, 2020, 57, 102866.	2.7	38
89	Rare ATG7 genetic variants predispose patients to severe fatty liver disease. Journal of Hepatology, 2022, 77, 596-606.	1.8	38
90	Increased insulin receptor substrate 2 expression is associated with steatohepatitis and altered lipid metabolism in obese subjects. International Journal of Obesity, 2013, 37, 986-992.	1.6	37

#	Article	IF	Citations
91	Hepcidin resistance in dysmetabolic iron overload. Liver International, 2016, 36, 1540-1548.	1.9	36
92	TNFÎ± genotype affects TNFÎ± release, insulin sensitivity and the severity of liver disease in HCV chronic hepatitis. Journal of Hepatology, 2005, 43, 944-950.	1.8	35
93	Implications of <scp>PNPLA</scp>3 polymorphism in chronic hepatitis <scp>C</scp> patients receiving peginterferon plus ribavirin. Alimentary Pharmacology and Therapeutics, 2012, 35, 1434-1442.	1.9	35
94	Effect of the A736V TMPRSS6 polymorphism on the penetrance and clinical expression of hereditary hemochromatosis. Journal of Hepatology, 2012, 57, 1319-1325.	1.8	33
95	Nonalcoholic fatty liver disease or metabolic dysfunctionâ€associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches. European Journal of Clinical Investigation, 2021, 51, e13519.	1.7	32
96	Genetics Is of the Essence to Face NAFLD. Biomedicines, 2021, 9, 1359.	1.4	30
97	Iron Stores, Hepcidin, and Aortic Stiffness in Individuals with Hypertension. PLoS ONE, 2015, 10, e0134635.	1.1	28
98	HFE Mutations Modulate the Effect of Iron on Serum Hepcidin-25 in Chronic Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1331-1337.	2.2	27
99	Leptin, Resistin, and Proprotein Convertase Subtilisin/Kexin Type 9. American Journal of Pathology, 2020, 190, 2226-2236.	1.9	26
100	PCSK9 rs11591147 R46L lossâ€ofâ€function variant protects against liver damage in individuals with NAFLD. Liver International, 2021, 41, 321-332.	1.9	26
101	Dysmetabolic Hyperferritinemia and Dysmetabolic Iron Overload Syndrome (DIOS): Two Related Conditions or Different Entities?. Current Pharmaceutical Design, 2020, 26, 1025-1035.	0.9	26
102	Mutant PNPLA3 I148M protein as pharmacological target for liver disease. Hepatology, 2017, 66, 1026-1028.	3.6	25
103	Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis. Gastroenterology, 2017, 153, 1568-1580.e10.	0.6	25
104	A tetra-primer amplification refractory mutation system polymerase chain reaction for the evaluation of rs12979860 IL28B genotype. Journal of Viral Hepatitis, 2011, 18, 628-630.	1.0	24
105	Hepatic steatosis and <scp>PNPLA</scp>3 I148<scp>M</scp> variant are associated with serum <scp>F</scp>etuinâ€<scp>A</scp> independently of insulin resistance. European Journal of Clinical Investigation, 2014, 44, 627-633.	1.7	24
106	mir-101-3p Downregulation Promotes Fibrogenesis by Facilitating Hepatic Stellate Cell Transdifferentiation During Insulin Resistance. Nutrients, 2019, 11, 2597.	1.7	24
107	MAFLD in COVID-19 patients: an insidious enemy. Expert Review of Gastroenterology and Hepatology, 2020, 14, 867-872.	1.4	23
108	Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC. International Journal of Molecular Sciences, 2021, 22, 4173.	1.8	23

#	Article	IF	Citations
109	Peroxisome Proliferator-Activated Receptor Genetic Polymorphisms and Nonalcoholic Fatty Liver Disease: Any Role in Disease Susceptibility?. PPAR Research, 2013, 2013, 1-8.	1.1	21
110	The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: TMPRSS6 and hepcidin in hemodialysis. BMC Nephrology, 2013, 14, 48.	0.8	20
111	HFE Gene Mutations and Oxidative Stress Influence Serum Ferritin, Associated with Vascular Damage, in Hemodialysis Patients. American Journal of Nephrology, 2007, 27, 101-107.	1.4	19
112	Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Hepatology Communications, 2022, 6, 535-549.	2.0	18
113	Lipid accumulation impairs lysosomal acid lipase activity in hepatocytes: Evidence in NAFLD patients and cell cultures. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2019, 1864, 158523.	1.2	17
114	Adipocyte PHLPP2 inhibition prevents obesity-induced fatty liver. Nature Communications, 2021, 12, 1822.	5.8	17
115	Iron overload induces hypogonadism in male mice via extrahypothalamic mechanisms. Molecular and Cellular Endocrinology, 2017, 454, 135-145.	1.6	16
116	The rs599839 A>G Variant Disentangles Cardiovascular Risk and Hepatocellular Carcinoma in NAFLD Patients. Cancers, 2021, 13, 1783.	1.7	16
117	FGF23 and Fetuin-A Interaction in the Liver and in the Circulation. International Journal of Biological Sciences, 2018, 14, 586-598.	2.6	15
118	PSD3 downregulation confers protection against fatty liver disease. Nature Metabolism, 2022, 4, 60-75.	5.1	15
119	Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies. Biomedicines, 2022, 10, 182.	1.4	15
120	TNFÎ± Promoter Polymorphisms. , 2004, 98, 047-058.		14
121	Liver transplantation for hepatocellular carcinoma in a patient with a novel telomerase mutation and steatosis. Journal of Hepatology, 2013, 58, 399-401.	1.8	14
122	<i>HFE</i> Genotype Influences Erythropoiesis Support Requirement in Hemodialysis Patients: A Prospective Study. American Journal of Nephrology, 2008, 28, 311-316.	1.4	13
123	FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage. Clinical Gastroenterology and Hepatology, 2020, 18, 517-519.	2.4	12
124	HFEmutations in nonalcoholic fatty liver disease. Hepatology, 2008, 47, 1794-1795.	3.6	11
125	The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation. EBioMedicine, 2021, 65, 103249.	2.7	11
126	What is the contribution of differences in three measures of tumor necrosis factor-alpha activity to insulin resistance in healthy volunteers?. Metabolism: Clinical and Experimental, 2003, 52, 1593-1596.	1.5	10

#	Article	IF	Citations
127	Particulate matter phagocytosis induces tissue factor in differentiating macrophages. Journal of Applied Toxicology, 2016, 36, 151-160.	1.4	10
128	Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158765.	1.2	10
129	Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC. Biomedicines, 2021, 9, 1524.	1.4	10
130	Interaction between Lifestyle Changes and PNPLA3 Genotype in NAFLD Patients during the COVID-19 Lockdown. Nutrients, 2022, 14, 556.	1.7	10
131	Reply. Hepatology, 2015, 62, 660-660.	3.6	9
132	Interaction between PNPLA3 I148M Variant and Age at Infection in Determining Fibrosis Progression in Chronic Hepatitis C. PLoS ONE, 2014, 9, e106022.	1.1	9
133	Effluent Molecular Analysis Guides Liver Graft Allocation to Clinical Hypothermic Oxygenated Machine Perfusion. Biomedicines, 2021, 9, 1444.	1.4	9
134	Variants in PCSK7, PNPLA3 and TM6SF2 are risk factors for the development of cirrhosis in hereditary haemochromatosis. Alimentary Pharmacology and Therapeutics, 2021, 53, 830-843.	1.9	9
135	PD-1/PD-L1 Immuno-Mediated Therapy in NAFLD: Advantages and Obstacles in the Treatment of Advanced Disease. International Journal of Molecular Sciences, 2022, 23, 2707.	1.8	9
136	Bloodletting Ameliorates Insulin Sensitivity and Secretion in Parallel to Reducing Liver Iron in Carriers of HFE Gene Mutations: Response to Equitani et al.. Diabetes Care, 2008, 31, e18-e18.	4.3	8
137	CDKN1A: A double-edged sword in fatty liver?. Cell Cycle, 2014, 13, 1371-1372.	1.3	8
138	A novel alpha1-antitrypsin null variant (PiQ0Milano). World Journal of Hepatology, 2013, 5, 458.	0.8	8
139	MAFLD definition underestimates the risk to develop HCC in genetically predisposed patients. Journal of Internal Medicine, 2022, 291, 374-376.	2.7	8
140	Impact of natural neuromedinâ€Β receptor variants on iron metabolism. American Journal of Hematology, 2020, 95, 167-177.	2.0	7
141	From Environment to Genome and Back: A Lesson from HFE Mutations. International Journal of Molecular Sciences, 2020, 21, 3505.	1.8	7
142	Cutting-Edge Therapies and Novel Strategies for Acute Intermittent Porphyria: Step-by-Step towards the Solution. Biomedicines, 2022, 10, 648.	1.4	7
143	Increased circulating adiponectin in males with chronic HCV hepatitis. European Journal of Internal Medicine, 2015, 26, 635-639.	1.0	6
144	NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease. Liver International, 2021, 41, 2712-2719.	1.9	6

#	Article	IF	Citations
145	Juvenile hemochromatosis associated with heterozygosity for novel hemojuvelin mutations and with unknown cofactors. Annals of Hepatology, 2014, 13, 568-571.	0.6	5
146	GNPAT p.D519G variant and iron metabolism during oral iron tolerance test. Hepatology, 2017, 65, 384-385.	3.6	5
147	Genetic variants in the MTHFR are not associated with fatty liver disease. Liver International, 2020, 40, 1934-1940.	1.9	5
148	Î±-Lipoic Acid Improves Hepatic Metabolic Dysfunctions in Acute Intermittent Porphyria: A Proof-of-Concept Study. Diagnostics, 2021, 11, 1628.	1.3	5
149	Genetic and metabolic factors: the perfect combination to treat metabolic associated fatty liver disease. Exploration of Medicine, 2020, 1, 218-243.	1.5	4
150	Iron genes, dysmetabolism and fibrosis in chronic hepatitis C. Journal of Hepatology, 2008, 48, 513-514.	1.8	3
151	Can nonalcoholic steatohepatitis trigger porphyria cutanea tarda clinical manifestations?. Internal and Emergency Medicine, 2009, 4, 91-92.	1.0	3
152	Ferroportin-1 in the recurrence of hepatic iron overload after liver transplantation. Digestive and Liver Disease, 2009, 41, e17-e20.	0.4	3
153	Serum hyaluronic acid for the screening of progressive nonalcoholic steatohepatitis in children: a promising approach. Translational Research, 2010, 156, 226-228.	2.2	3
154	MBOAT7 locus rs641738 variant predisposes to hepatocellular carcinoma in nonalcoholic fatty liver. Digestive and Liver Disease, 2016, 48, e7-e8.	0.4	3
155	Rare ceruloplasmin variants are associated with hyperferritinemia and increased hepatic iron in NAFLD patients: results from a NGS study. Journal of Hepatology, 2018, 68, S58-S59.	1.8	3
156	Tâ€ARMSâ€PCR for the evaluation of rs12979860 IL28B genotype: an optimized protocol. Journal of Viral Hepatitis, 2012, 19, 228-228.	1.0	2
157	IL28B rs12979860 polymorphism influences serum TNFalpha levels in chronic hepatitis C. Digestive and Liver Disease, 2013, 45, 348-349.	0.4	2
158	Non-alcoholic fatty liver disease and cardiovascular disease: A still debated liaison. European Journal of Preventive Cardiology, 2020, 27, 1056-1058.	0.8	2
159	Insulin resistance and tnf alpha polymorphism in Italian patients with non alcoholic fatty liver disease (NAFLD). Journal of Hepatology, 2001, 34, 235.	1.8	1
160	Correspondence. Digestive and Liver Disease, 2003, 35, 596-597.	0.4	1
161	Juvenile hemochromatosis associated with heterozygosity for novel hemojuvelin mutations and with unknown cofactors. Annals of Hepatology, 2014, 13, 568-71.	0.6	1
162	TNF alpha and hereditary hemocromatosis: possible interactions. Journal of Hepatology, 2001, 34, 218.	1.8	0

#	Article	IF	Citations
163	CTLA-4 recipient polymorphism influences HCV liver disease recurrence following orthotopic liver transplantation (OLT). Journal of Hepatology, 2002, 36, 43.	1.8	0
164	Cytotoxic T-lymphocyte antigen 4 is associated with development and progression of alcoholic liver disease (ALD) in Italian patients. Journal of Hepatology, 2002, 36, 66.	1.8	0
165	Liver fat accumulation is associated with circulating PCSK9 levels. Digestive and Liver Disease, 2015, 47, e230.	0.4	0
166	Reply to â€œStatin treatment for non-alcoholic steatohepatitisâ€. Journal of Hepatology, 2016, 64, 242-243.	1.8	0
167	Impact of Neuromedin-B receptor variants on iron overload disorders. Digestive and Liver Disease, 2018, 50, 25.	0.4	0
168	Impact of Proprotein Convertase Subtilisin/Kexin Type 7 genetic variation in patients with non-alcoholic fatty liver disease. Digestive and Liver Disease, 2018, 50, 19.	0.4	0
169	PS-005-Evaluation of neuromedin-B receptor variants effect on iron metabolism and liver disease. Journal of Hepatology, 2019, 70, e7-e8.	1.8	0
170	PS-006-MBOAT7 downregulation induces hepatic lipid accumulation. Journal of Hepatology, 2019, 70, e8.	1.8	0
171	THU-323-Impact of genetic polymorphisms associated with NAFLD on hepatic and vascular complications in diabetes. Journal of Hepatology, 2019, 70, e302.	1.8	0
172	FRI-320-TM6SF2 silencing impairs lipid metabolism and trafficking in HepG2 cells carrying the I148M PNPLA3 variant and MBOAT7 deletion. Journal of Hepatology, 2019, 70, e536-e537.	1.8	0
173	FRI-333-ATG7 genetic variant and defective autophagy: A novel risk factor for non-alcoholic fatty liver disease progression in patients with type 2 diabetes mellitus. Journal of Hepatology, 2019, 70, e542.	1.8	0
174	Risk of liver disease in first-degree relatives of patients with advanced NAFLD: initial data from an Italian cohort study. Digestive and Liver Disease, 2019, 51, e23.	0.4	0
175	Transcriptomics highlights interleukin-32 a novel biomarker showing higher accuracy in carriers of the pnpla3 i148m variant. Digestive and Liver Disease, 2019, 51, e30-e31.	0.4	0
176	Rare Atg7 Genetic Variants Predispose to Severe Fatty Liver Disease. SSRN Electronic Journal, 0, , .	0.4	0
177	<i>NR1H4</i> rs35724 G>C Variant Modulates Liver Damage in Nonalcoholic Fatty Liver Disease. SSRN Electronic Journal, 0, , .	0.4	0